* If you want to update the article please login/register
Background/Aims: Serum phosphate has been attributed to adverse events in patients with chronic kidney disease. Salivary phosphate has been suggested as a potential object of therapy with a chitosan-containing chewing gum. Methods: We conducted several pilot studies to characterize Psal and its relationship with kidney disease, then conducted two clinical trials: a double-blind placebo-controlled trial in patients with end-stage renal disease and an open-label trial in those with stage 3-4 CKD. Compared to the original collection, the Passive saliva collection had a higher Psal concentration. In a two-week open-label trial in patients with CKD not on dialysis, the 20 mg chitosan gum administered three times a day reduced serum P by 0. 05 mmol/l. There was no improvement in Psal with chitosan gum in either trial. A drop of serum P of about 0. 05-0. 065 mmol/l was achieved by chewing gum in Chitosan, but had no effect on Psal concentrations.
Source link: https://doi.org/10.1159/000351850
* Please keep in mind that all text is summarized by machine, we do not bear any responsibility, and you should always check original source before taking any actions